Seegene and QIAGEN Enter Agreement to Develop Molecular Diagnostic Assays

Seegene (KOSDAQ:096530) and Qiagen (NASDAQ:QGEN) have entered into an agreement to develop and supply multiplex molecular diagnostic assays. This is the second deal of this type that Seegene has entered into.
As quoted in the press release:

Under the terms of the agreement, Seegene will develop and manufacture multiplex infectious disease testing panels exclusively designed for QIAGEN’s real-time PCR cycler Rotor-Gene Q, member of QIAGEN’s QIAsymphony family of automated instruments, and QIAGEN will have worldwide commercialization rights to these tests.
… This is the second major global original design manufacturing (ODM) deal that Seegene has entered into. In November 2014, Seegene and Beckman Coulter inked a deal under which Seegene will manufacture reagents designed exclusively for Beckman Coulter’s new Veris MDx sample-to-answer molecular diagnostics system.

Seegene CEO, Dr. Jong-Yoon Chun, said:

This is an exciting partnership that will deliver a very powerful tool providing a more comprehensive and actionable diagnosis to clinicians worldwide. QIAGEN’s IVD market leadership will also help to further grow our multiplex real-time PCR diagnostic testing footprint in disease indications that are in need of powerful new diagnostics.

Click here to read the full Seegene (KOSDAQ:096530) press release.